Johnson & Johnson is committed to developing procurement relationships based on trust. We drive growth while maintaining the highest standards through industry-leading supplier innovation, quality and reliability.
Growth & Innovation
We aim to own and shape a diverse supplier base that delivers high quality, compliant and reliable products and services.
Our suppliers are encouraged to source innovative solutions, and deliver new business models that contribute to our mutual objectives for growth and streamlined processes. We embrace new technology whenever it may help us meet the needs of our patients and consumers.
Investing in Our Future
We track new market developments and seek suppliers who understand emerging trends and plan their business accordingly. We forge long-term relationships with organizations that collaborate with us to successfully bring their innovations to the marketplace.
We follow a procurement approach that is rooted in Our Credo. We strive to obtain the highest-quality products and services at a fair cost, representing the best overall value for our companies.
Global Diversity, Citizenship and Sustainability
Embracing our role as an industry leader, Johnson & Johnson shapes and upholds the highest standards for responsible sourcing and corporate citizenship.
We further differentiate Johnson & Johnson by working with suppliers to accelerate environmental and social improvements across the value chain. We anticipate and manage risk, and ensure compliance with all procurement policies and processes.
Develop Our Diverse, Global Supply Base
We build and develop a global group of suppliers that reflects the diversity of our patients and customers, and our commitment to inclusion. The Supplier Diversity Program is designed to ensure that businesses of diverse backgrounds and ownership have the opportunity to become valued suppliers.
Since starting our Supplier Diversity Program in 1998, our total spending with small businesses and diverse-owned suppliers has been over one billion dollars annually.
With its Phase 3 clinical trial now fully enrolled, the Global Head of Research & Development at Janssen brings us up to speed on the progress of the company's vaccine candidate, including upcoming key milestones.
With COVID-19 dominating the news this year, chances are you've also read about clinical studies that are underway for investigational vaccines. For a glimpse at what the experience of participating in a clinical study is like, we spoke to people across the country who took part in a clinical trial.
On the final Season 2 episode of The Road to a Vaccine, host Lisa Ling delved into what it will take to overcome the pandemic in the U.S. Penn and Lee, two of the show's guests, shared what they've learned over the past nine months through their work helping provide testing across the country.